US FDA approves Genfit and Ipsen's liver disease drug
10/06/2024 22:02
June 10 (Reuters) - The U.S. Food and Drug Administration has approved French drugmakers Ipsen IPN.PA and Genfit's GNFT.PA drug to treat a chronic inflammatory liver disease, Ipsen said on Monday. (Reporting by Puyaan Singh in Bengaluru; Editing by Alan Barona) ((Puyaan.Singh@thomsonreuters.com;))
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients